Comparison of Arbutus Biopharma and Immunome's Financial Metrics
1 report, 1 independent
Updated Oct 12
AI-generated briefing. Brind wrote this from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
A comparison of Arbutus Biopharma and Immunome showed differences in financial metrics and ownership structures. Arbutus Biopharma reported higher revenue and earnings compared to Immunome. While Immunome has a consensus target price indicating a potential upside of 75.19%, Arbutus Biopharma's consensus target price suggests an upside of 18.48%.
From themarketsdaily.com
Why it matters
The comparison highlights differing levels of institutional and insider ownership between the two companies. Analysts noted that Immunome's consensus rating was stronger and indicated a higher possible upside than Arbutus Biopharma's.
From themarketsdaily.com
Who's involved
- Arbutus BiopharmaCanadian Bio Tech Company competing for investment funding
- MarketBeatAmerican personal finance blog used by Arbutus Biopharma for financial reporting
- PfizerAmerican multinational pharmaceutical and biotechnology corporation against whom Arbutus Biopharma has filed patent lawsuits
- MedicalPlastic Surgeon in the sector where Arbutus Biopharma is contextualized
Keep exploring
The entities involved
-
Arbutus Biopharma
Canadian Bio Tech Company
Nothing else this week.
Related events
- Both Arbutus Biopharma and Prelude Therapeutics are small-cap healthcare companies, with Arbutus having higher revenue and earnings.
- Arbutus Biopharma and Evaxion A/S are identified as small-cap healthcare companies.
- Arbutus Biopharma and Prelude Therapeutics are identified as small-cap healthcare companies.